Hematologic Malignancy
Leukemic Phase of Non-Hodgkin Lymphoma
CI-CAN-00003025Explore in graph →
Hematologic12 active trials1 evidence items
- NCIt
- C8594
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003025Explore in graph →
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome | terminated | Phase 4 | 7 | Vanderbilt University Medical CenterOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 |
| Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
| completed |
| Phase 4 |
| 86 |
| Eisai Inc.INDUSTRY |
| 9 |
| Mar 5, 2008 |
| clinicaltrials |
Data updated 22 days agoSource updated May 10, 2017source: clinicaltrials